scroll to top of page

Clinical Trials

Clinical trials are research studies designed to discover new ways to treat different cancers, and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.

Thompson was the first to bring cancer clinical trials to East Tennessee more than 25 years ago. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.

Brain

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.

Protocol Number NCT Number Summary Principal Investigator
A221101 NCT01781468 For patients with high grade gliomas that experience fatigue after their treatment, to see if adding a pill (Armodafinil) after the cancer treatment will help with cancer related fatigue.  Grant Clark, MD

Breast

Protocol Number NCT Number Summary Principal Investigator
NSABP  B-51/RTOG 1304 NCT01872975 A study for women with early stage breast cancer to determine if giving less radiation is as effective as traditional radiation in patients who have had a very good response to chemotherapy received prior to surgery.   Grant Clark, MD
SWOG S1207/NSABP B-53 NCT01674140 A study for high-risk HER2 negative, hormone receptor-positive breast cancer to determine if adding a pill (Everolimus) to standard hormonal treatment after patients have received their chemotherapy and/or radiation therapy, will decrease the risk of breast cancer returning.  Wenqing Zhang, MD
S1418 NCT02954874 For patients with high risk “triple negative” breast cancer, a study to see if using an immunotherapy (Pembrolizumab) after the usual treatments will help keep breast cancer from returning.  Jashmin Patel, MD

Gastrointestinal

Protocol Number NCT Number Summary Principal Investigator
A021502 NCT02912559 For patients with stage III colon cancer with deficient mismatch repair, to see if adding an immunotherapy (Atezolizumab) to the usual chemotherapy given after surgery will decrease the chance of cancer returning.    Wenquing Zhang, MD

Genitourinary

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Gynecologic

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Head and Neck

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Leukemia/Lymphoma

Protocol Number NCT Number Summary Principal Investigator
CONNECT AZA-MDS-006 n/a For patients with new Leukemia and MDS, this study is gathering information about how patients feel when being treated for this cancer, what kind of medicine they are taking, and how their medicine is affecting them.  Everett Ribakove, MD
UNITY-NHL (UTX-TGR-205) NCT02793583 For patients who have had a recurrence of Non-Hodgkin’s Lymphona after treatement. A study to test whether a pill (TGR-1202) and/or immunotherapy (Ublituximab) is effective at treating lymphoma.  Wenqing Zhang, MD

Lung: Non-Small Cell

Protocol Number NCT Number Summary Principal Investigator
Cypress-1 (AM0010-201) NCT03382899 For patients with new metastatic (stage IV) Non-Small Cell Lung cancer, to see if adding a subcutaneous injection of AM0010 (a new cancer treatment) in combination with immunotherapy (Pembrolizumab) is more effective that immunotherapy alone.  Everett Ribakove, MD
Cypress-2 AM0010-202 NCT03382912 For patients with previously treated metastatic (stage IV) Non-Small Cell Lung cancer, to see if adding a subcutaneous injection of AM0010 (a new cancer treatment) in combination with immunotherapy (Nivolumab) is more effective than immunotherapy alone.  Everett Ribakove, MD

Lung: Small Cell

Protocol Number NCT Number Summary Principal Investigator
CALGB 30610 NCT00632853 A study for limited stage small cell lung cancer to compare two different ways to give radiation therapy to see which is more effective. In addition, every patient will get chemotherapy with Cisplatin and Etoposide, which is standard treatment for this type of lung cancer.  Grant Clark, MD

Melanoma

Protocol Number NCT Number Summary Principal Investigator
EA6134 NCT02224781 A study to determine which is the best sequence (targeted therapy followed by immunotherapy, or immunotherapy followed by targeted therapy) for treating patients with advanced BRAF positive melanoma. The medications include: Dabrafenib, Trametinib, Ipilimumab, and Nivolumab.  Wenquing Zhang, MD

Multiple Myeloma

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Recurrent Tumors, Lymphomas, and Multiple Myeloma

Protocol Number NCT Number Summary Principal Investigator
EAY 131 MATCH NCT02465060 A study to test more than 25 different treatments for patients with recurrent or rare cancers with a molecular profile that “matches” a targeted therapy.  Wenquing Zhang, MD